Prot# PR-022: A Six Month, Safety Follow-up Study in Subjects with Eosinophilic Esophagitis (EoE) who Completed Study PR-021 [PR-021: A multicenter, randomized, double-blind, placebo-controlled, safety and tolerability phase 1/2a study of two dosing regim

Project: Research project

Project Details

StatusFinished
Effective start/end date3/30/123/30/15

Funding

  • Medpace, Inc. (PR-022)
  • Aptalis Pharma US, Inc. (PR-022)